GlassScriptPhysician profile
Emmanuel Apor
NPI 1295028405
$1,481.75
in general payments reported to CMS, 2019-2025
25 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $235 · 2021: $17.83 · 2022: $23.79 · 2023: $16.53 · 2024: $269 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.46 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $302.76 | 2019-2025 | Imdelltra (Amg757) |
| Merck Sharp & Dohme LLC | $191.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $145.90 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $140.80 | 2019-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $137.45 | 2019-2022 | |
| Geron Corporation | $97.48 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $57.77 | 2019-2025 | Fruzaqla |
| Lilly USA, LLC | $49.32 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $48.05 | 2019-2024 | Libtayo |
| Janssen Biotech, INC. | $32.51 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $30.76 | 2019-2023 | Epkinly, Imbruvica |
| Celgene Corporation | $29.28 | 2019 | |
| Pfizer INC. | $27.71 | 2019 | |
| Adaptive Biotechnologies Corporation | $21.30 | 2025 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $19.07 | 2024 | Monoferric |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $18.75 | 2019 | |
| Daiichi Sankyo INC. | $15.93 | 2020 | |
| Foundation Medicine, INC. | $14.99 | 2020 | |
| Incyte Corporation | $14.93 | 2019 | |
| Astellas Pharma US INC | $14.68 | 2019 | |
| Gilead Sciences, INC. | $14.37 | 2019 | |
| Genentech USA, INC. | $14.34 | 2019 | |
| Eisai INC. | $14.27 | 2019 | |
| Genzyme Corporation | $14.25 | 2019 | |
| Tesaro, INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Apor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.